Molecular diagnostic trends in urological cancer: Biomarkers for non-invasive diagnosis

V. Urquidi, C. J. Rosser, S. Goodison

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.

Original languageEnglish (US)
Pages (from-to)3653-3663
Number of pages11
JournalCurrent Medicinal Chemistry
Issue number22
StatePublished - Aug 2012


  • Biomarkers
  • Body fluids
  • Diagnosis
  • Non-invasive
  • Urinary
  • Urological cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Molecular diagnostic trends in urological cancer: Biomarkers for non-invasive diagnosis'. Together they form a unique fingerprint.

Cite this